Shares of Bioblast Pharma Ltd (NASDAQ:ORPN) shot up 22.4% on Friday . The company traded as high as $4.44 and last traded at $3.00. 3,587,987 shares were traded during mid-day trading, an increase of 296% from the average session volume of 906,831 shares. The stock had previously closed at $2.45.

Separately, ValuEngine upgraded shares of Bioblast Pharma from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 26th.

The company has a market capitalization of $10.03, a P/E ratio of -1.17 and a beta of -0.05.

Bioblast Pharma (NASDAQ:ORPN) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at

Bioblast Pharma Company Profile

Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.

Receive News & Ratings for Bioblast Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioblast Pharma and related companies with's FREE daily email newsletter.